Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06742307
PHASE4

Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration

Sponsor: Hospital Authority, Hong Kong

View on ClinicalTrials.gov

Summary

We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.

Official title: Faricimab Fixed Quarterly Maintenance for Neovascular Age Related Macular Degeneration: A Prospective Case Series

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-08-21

Completion Date

2027-02-01

Last Updated

2025-10-01

Healthy Volunteers

No

Interventions

DRUG

Faricimab Injection [Vabysmo]

A planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.

Locations (1)

Department of Ophthalmology, United Chrisitian Hospital

Hong Kong, Hong Kong